Package Leaflet: Information for the User
Trizivir 300 mg/150 mg/300 mg film-coated tablets
abacavir/lamivudine/zidovudine
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
IMPORTANT — Hypersensitivity Reactions
Trizivir contains abacavir(which is also the active substance in medicines such as Kivexa, Triumeqand Ziagen). Some people who take abacavir may develop a hypersensitivity reaction(severe allergic reaction), which can be life-threatening if they continue to take medicines containing abacavir.
You must read carefully the information about “Hypersensitivity Reactions” in section 4 of this leaflet.
The packaging of Trizivir includes an Information Cardto remind you and your healthcare provider of hypersensitivity to Trizivir. You must remove this card and always carry it with you.
Contents of the pack
Trizivir is used in the treatment of HIV (Human Immunodeficiency Virus) infection in adults.
Trizivir contains three active substances used to treat HIV infection: abacavir, lamivudine, and zidovudine. All of them belong to a group of antiretroviral medicines called nucleoside analogue reverse transcriptase inhibitors(NRTIs).
Trizivir helps to control your disease. Trizivir does not cure HIV infection; it reduces the amount of virus in your body and keeps it at a low level. This helps your body to increase the number of CD4 cells in your blood. CD4 cells are a type of white blood cell that plays an important role in helping your body to fight infection.
Not everyone responds to treatment with Trizivir in the same way. Your doctor will monitor the effectiveness of your treatment.
Read carefully all the information about “Hypersensitivity Reactions” in section 4 of this leaflet.
Talk to your doctorif you think any of these apply to you.
Be especially careful with Trizivir
Some people who take Trizivir have a higher risk of getting serious side effects. You need to know that there is a higher risk:
if you have moderate or severe liver disease
if you have ever had liver disease, including hepatitis B or C (if you have hepatitis B, do not stop taking Trizivir without your doctor's advice, as it may get worse)
if you are overweight(especially if you are a woman).
Talk to your doctor before you start taking Trizivir ifyou have any of these conditions. You may need extra checks, including blood tests, while you are taking this medicine. For more information, see section 4.
Hypersensitivity reactions to abacavir
Even patients who do not have the HLA-B*5701 gene may develop a hypersensitivity reaction(a severe allergic reaction). Read carefully all the information about hypersensitivity reactions in section 4 of this leaflet.
Some people who take Trizivir develop other conditions, which can be serious. You need to know what important signs and symptoms to look out for while you are taking Trizivir.
Read the information about “Other possible side effects of Trizivir” in section 4 of this leaflet.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription, and herbal medicines.
Remember to tell your doctor or pharmacist if you start taking any new medicines while you are taking Trizivir.
These medicines must not be taken with Trizivir:
stavudine or emtricitabine to treat HIV infection
other medicines that contain lamivudine, used to treat HIV infectionor hepatitis B
ribavirin or ganciclovir injections to treat viral infections
high doses of co-trimoxazole(a combination of trimethoprim and sulfamethoxazole), an antibiotic
cladribine, used to treat hairy cell leukaemia.
Tell your doctorif you are being treated with any of these medicines.
Some medicines may increase the chance of getting side effects, or make them worse
These include:
Tell your doctorif you are taking any of these medicines.
Some medicines interact with Trizivir
These include:
If you are taking clarithromycin, take your dose at least 2 hours before or after taking Trizivir.
Tell your doctorif you are taking phenytoin. Your doctor may decide to monitor you while you are taking Trizivir.
Tell your doctor or pharmacistif you are being treated with any of these.
It may be necessary for your doctor to reduce your dose of riociguat, as abacavir may increase the levels of riociguat in your blood.
Methadone and Trizivir
Abacavir increases the rate at which methadone is removed from the body. If you are taking methadone, you may need to be monitored for signs of withdrawal. You may need your methadone dose to be changed.
If you are pregnant, or think you may be pregnant, or if you are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Trizivir and similar medicines may cause side effects in babies when taken during pregnancy. If you have taken Trizivir during your pregnancy, your doctor may request that you have regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.
It is recommended that HIV-infected women do not breast-feed their babiesbecause HIV can be passed to the baby through breast milk. A small amount of the components of Trizivir may also pass into breast milk.
If you are breast-feeding or thinking of breast-feeding, consult your doctor as soon as possible.
Trizivir may cause dizzinessand have other effects that reduce your alertness.
Do not drive or operate machineryunless you feel well.
Important information about some of the ingredients of Trizivir tablets
This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Stay in touch with your doctor and do not stop taking Trizivirwithout talking to your doctor first.
The usual dose for adults is one tablet twice a day.
Take the tablets at regular intervals, allowing approximately 12 hours between each tablet.
Swallow the tablets whole with a little water. Trizivir can be taken with or without food.
If you accidentally take too much Trizivir, tell your doctor or pharmacist or contact the emergency department of your nearest hospital for advice.
If you forget to take Trizivir
If you miss a dose, take it as soon as you remember and then continue with your treatment as before.
Do not take a double dose to make up for a forgotten dose.
It is important to take Trizivir regularly, as irregular intake can make Trizivir less effective against HIV infection and may increase the risk of hypersensitivity reactions.
If for any reason you have stopped taking Trizivir — especially because you think you have had side effects or because of another illness:
Talk to your doctor before you start taking Trizivir again. Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If your doctor thinks that they may have been related, they will tell you that you must never take Trizivir or any other medicine that contains abacavir (Kivexa, Triumeq, or Ziagen) again. It is very important that you follow this advice.
If your doctor advises you to restart treatment with Trizivir, they may ask you to take the first doses in a place where you can easily get medical help if you need it.
During treatment for HIV, you may experience an increase in weight and levels of glucose and fats in the blood. This may be due in part to the recovery of your natural immune system and to the lifestyle changes and, in the case of blood fats, to the HIV medicines themselves. Your doctor will monitor these changes.
Treatment with Trizivir often causes loss of fat from the legs, arms, and face (lipoatrophy). This loss of body fat has been shown to be not completely reversible after stopping zidovudine. Your doctor should monitor you for signs of lipoatrophy. If you notice any loss of fat from your legs, arms, and face, tell your doctor. When these symptoms occur, you should stop taking Trizivir and change your HIV treatment.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
When you are being treated for HIV, it can be difficult to tell whether a symptom is a side effect of Trizivir or of other medicines you are taking, or a result of the HIV infection itself. Therefore, it is very important that you tell your doctor about any changes in your health.
Even patients who do not have the HLA-B*5701 gene may develop a hypersensitivity reaction(a severe allergic reaction), described in this leaflet in the section called “Hypersensitivity Reactions”.
It is very important that you read and understand the information about this serious reaction.
In addition to the side effects listed below for Trizivir, other conditions can develop during treatment.
It is important that you read on the other side of the leaflet the information under the heading “Other possible side effects of Trizivir”.
Hypersensitivity Reactions
Trizivircontains abacavir(the active substance that is also present in Kivexa, Triumeq, and Ziagen).
Abacavir can cause a severe allergic reaction known as a hypersensitivity reaction. These hypersensitivity reactions have been seen more frequently in people taking medicines that contain abacavir.
Anyone who is taking Trizivir could develop a hypersensitivity reaction to abacavir, which could be life-threatening if they continue to take Trizivir.
You are more likely to develop this reaction if you have a gene called HLA-B*5701(but you can still get this reaction even if you do not have this gene). Before you start treatment with Trizivir, you should have been tested for this gene. If you know you have this gene, tell your doctor before you take Trizivir.
About 3 to 4 in every 100 patients treated with abacavir in a clinical trial who did not have the HLA-B*5701 gene developed a hypersensitivity reaction.
The most common symptoms are:
Other common signs include:
Other symptoms may include:
Joint or muscle pain, swelling of the neck, difficulty breathing, sore throat, cough, headache, inflammation of the eye (conjunctivitis), mouth ulcers, low blood pressure, and tingling or numbness of the hands or feet.
Hypersensitivity reactions can occur at any time during treatment with Trizivir, but are more likely to happen in the first 6 weeks of treatment.
1if you have a skin rash OR
2if you have symptoms including at least 2 of the following groups:
Your doctor may advise you to stop taking Trizivir.
If you have stopped taking Trizivir due to a hypersensitivity reaction, NEVER TAKE Trizivir or any other medication that contains abacavir (Kivexa, Triumeq, or Ziagen) AGAIN. If you do, you may experience a drop in blood pressure that can be life-threatening within hours.
If for any reason you have interrupted treatment with Trizivir - especially because you think you have side effects or another illness:
Consult your doctor before restarting treatment.
Your doctor will check if your symptoms were related to a hypersensitivity reaction. If your doctor considers that there may have been a relationship, they will indicatethat you should never take Trizivir or any other medication that contains abacavir (Kivexa, Triumeq, or Ziagen) again. It is essential that you follow this warning.
Occasionally, hypersensitivity reactions have developed in people who restart abacavir after having had a single symptom of those included in the Information Card before stopping it.
Very rarely, patients who have taken medications containing abacavir in the past without symptoms of hypersensitivity have developed a hypersensitivity reaction when restarting it.
If your doctor advises you to restart treatment with Trizivir, they may ask you to take the first doses in a place where you have easy access to medical assistance if needed.
If you are hypersensitive (allergic) to Trizivir, you must return all your unused Trizivir tablets to be safely disposed of. Consult your doctor or pharmacist.
The Trizivir packaging includes an Information Cardto remind you and healthcare staff about hypersensitivity reactions. Separate the card from the packaging and always carry it with you.
May affect more than 1 in 10people:
May affect up to 1 in 10people:
Common side effects that may appear in blood tests are:
May affect up to 1 in 100people:
Uncommon side effects that may appear in blood tests are:
May affect up to 1 in 1,000people:
Rare side effects that may appear in blood tests are:
May affect up to 1 in 10,000people:
If you notice any of these symptoms, contact a doctor urgently.
Very rare side effects that may appear in blood tests are:
If you consider that any of the side effects you are suffering from is severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Other possible side effects of Trizivir
Trizivir may cause other disorders to develop during HIV treatment.
People with advanced HIV infection (AIDS) have weakened immune systems and are more likely to suffer from severe infections (opportunistic infections). When these people start treatment, they may find that old infections, which were hidden, flare up, causing signs and symptoms of inflammation. These symptoms are probably due to an improvement in the body's immune response, which allows it to fight these infections. The symptoms usually include fever, plus any of the following:
In rare cases, since the immune system becomes stronger, it can also attack healthy body tissue (autoimmune disorders). The symptoms of autoimmune disorders may appear many months after you start taking medications for HIV treatment. The symptoms may include:
If you notice any symptoms of infection while taking Trizivir:
Inform your doctor immediately. Do not take any other medication for the infection without your doctor's advice.
Some people taking Trizivir develop a disorder called lactic acidosis, along with an increased liver size.
Lactic acidosis is due to an increase in lactic acid levels in the body. It is rare, and if it occurs, it usually develops after a few months of treatment. It can be potentially fatal, causing failure of internal organs.
Lactic acidosis is more likely to develop in patients who have some liver condition or in obese people (with significant overweight), especially women.
During treatment, your doctor will closely monitor any signs that may indicate you are developing lactic acidosis. If you notice any of the symptoms listed above or are concerned about any other symptom:
See your doctor as soon as possible.
Some people receiving combined HIV treatment may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). People are more likely to suffer from this disease:
If you notice any of these symptoms:
Inform your doctor.
Trizivir may also cause:
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the packaging. The expiration date is the last day of the month indicated.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active ingredients of each film-coated tablet are 300 mg of abacavir (as sulfate), 150 mg of lamivudine, and 300 mg of zidovudine.
The other ingredients are microcrystalline cellulose, sodium carboxymethyl starch, and magnesium stearate in the tablet core. The film coating of the tablet contains hypromellose, titanium dioxide, polyethylene glycol, aluminum lake of indigo carmine, and yellow iron oxide.
Trizivir film-coated tablets are marked with "GX LL1" on one side. They are green-blue in color and have a capsule shape. They are available in blister packs containing 60 tablets or in bottles of 60 tablets with a child-resistant closure.
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Netherlands
Manufacturer
Delpharm Poznan Spólka Akcyjna, ul. Grunwaldzka 189, 60-322 Poznan, Poland.
You can obtain more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien ViiV Healthcare srl/bv Tel: + 32 (0) 10 85 65 00 | Lithuania ViiV Healthcare BV Tel: + 370 80000334 |
Bulgaria ViiV Healthcare BV Tel: + 359 80018205 | Luxembourg/Luxemburg ViiV Healthcare srl/bv Belgium/Belgien Tel: + 32 (0) 10 85 65 00 |
Czech Republic GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Hungary ViiV Healthcare BV Ltd Tel: + 36 80088309 |
Denmark GlaxoSmithKline Pharma A/S Tel: + 45 36 35 91 00 dk-info@gsk.com | Malta ViiV Healthcare BV Tel: + 356 80065004 |
Germany ViiV Healthcare GmbH Tel: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com | Netherlands ViiV Healthcare BV Tel: + 31 (0) 33 2081199 |
Estonia ViiV Healthcare BV Tel: + 372 8002640 | Norway GlaxoSmithKline AS Tel: + 47 22 70 20 00 |
Greece GlaxoSmithKline Μονοπρ?σωπη A.E.B.E. Tel: + 30 210 68 82 100 | Austria GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
Spain Laboratorios ViiV Healthcare, S.L. Tel: + 34 900 923 501 es-ci@viivhealthcare.com | Poland GSK Services Sp. z o.o. Tel: + 48 (0)22 576 9000 |
France ViiV Healthcare SAS Tel: + 33 (0)1 39 17 6969 Infomed@viivhealthcare.com Croatia ViiV Healthcare BV Tel: + 385 800787089 | Portugal VIIVHIV HEALTHCARE, UNIPESSOAL, LDA Tel: + 351 21 094 08 01 viiv.fi.pt@viivhealthcare.com Romania ViiV Healthcare BV Tel: + 40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenia ViiV Healthcare BV Tel: + 386 80688869 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia ViiV Healthcare BV Tel: + 421 800500589 |
Italy ViiV Healthcare S.r.l Tel: + 39 (0)45 7741600 | Finland GlaxoSmithKline Oy Tel: + 358 (0)10 30 30 30 Finland.tuoteinfo@gsk.com |
Cyprus ViiV Healthcare BV Tel: + 357 80070017 | Sweden GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvia ViiV Healthcare BV Tel: + 371 80205045 | United Kingdom (Northern Ireland) ViiV Healthcare BV Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of last revision of this leaflet:
Detailed information on this medication is available on the European Medicines Agency website http://www.ema.europa.eu